Anaconda Biomed raises $17m for next-gen brain thrombectomy device

Anaconda Biomed said it raised nearly $17 million (€15 million) in a Series A round for the neurothrombectomy device it’s developing. The round, led by new investors Ysios Capital, Omega Funds and Banco Sabadell and prior backer Innogest Capital, is enough to carry the ANCD Brain device through validation & verification and clinical studies ahead of a CE Mark bid in the European Union, co-founder & CEO Ofir Arad said in prepared remarks. The proceeds are also earmarked for an initial approval submission to the FDA, Arad said. Ysios general partner Josep Sanfeliu and Omega Funds managing director Claudio Nessi joined Barcelona-based Ananconda’s board in connection with the Series A round, the company said. “This financing provides Anaconda Biomed  the capital necessary to substantially progress the development of our ANCD Brain device, including the validation and verification process, clinical studies to support the initial commercialization of ANCD Brain  in Europe, and an initial submission to FDA,” Arad said. “Furthermore, the addition of Josep and Claudio to our board will strengthen the extensive operational and financial expertise available to our management team.” “The investment in Anaconda Biomed is great news not only for the consolidation of the medtech ecosystem in Spain and Barcelona but also for the amazing work of the founders in putting together a disruptive medical device by combining excellent med...
Source: Mass Device - Category: Medical Devices Authors: Tags: Catheters Funding Roundup Neurological Anaconda Biomed Source Type: news